Contribution: Industrial Research Assistance Program – Contributions to Firms
Alectos Therapeutics Inc.
$250,000.00
Preclinical Characterization and Validation of Novel Inhibitors for CNS Disease
FY 2021-22 · 2021-10-15
Summary
The project will characterize and validate novel small molecule glucocerebrosidase 2 inhibitors as disease-modifying therapeutics for Parkinson’s disease.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Burnaby|Burnaby, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
851456152
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2022-06-30
Agreement Number
981188
Agreement Start Date
2021-10-15
Agreement Title
Preclinical Characterization and Validation of Novel Inhibitors for CNS Disease
Agreement Title (French)
Caractérisation préclinique et validation de nouveaux inhibiteurs pour les maladies du SNC
Agreement Type
Contribution
Agreement Value
$250,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The project will characterize and validate novel small molecule glucocerebrosidase 2 inhibitors as disease-modifying therapeutics for Parkinson’s disease.
Description (French)
Le projet permettra de caractériser et de valider de nouvelles petites molécules inhibitrices de la glucocérébrosidase 2 en tant que traitements modificateurs de la maladie de Parkinson.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Burnaby North--Seymour
Federal Riding (French)
Burnaby-Nord--Seymour
Federal Riding Number
59002
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
851456152
Recipient City
Burnaby|Burnaby
Recipient Country
CA
Recipient Legal Name
Alectos Therapeutics Inc.
Recipient Postal Code
V5A 4B5
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2021-2022-Q3-981188
